Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

被引：3

作者：

Phillips, Tycel ^{[1
]}

Lugtenburg, Pieternella ^{[2
]}

Kalsekar, Anupama ^{[3
]}

Mutebi, Alex ^{[3
]}

Wang, Anthony ^{[4
]}

Blaedel, Julie ^{[3
]}

Kosa, Katherine ^{[5
]}

Martin, Susan ^{[5
]}

Sacchi, Mariana ^{[3
]}

Thieblemont, Catherine ^{[6
,7
]}

机构：

[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA

[2] Erasmus MC, Dept Hematol, HOVON Lymphoma Working Grp, Canc Inst,Univ Med Ctr, Rotterdam, Netherlands

[3] Genmab, Princeton, NJ USA

[4] AbbVie Inc, N Chicago, IL USA

[5] RTI Hlth Solut, Ann Arbor, MI USA

[6] Hop St Louis, AP HP, Paris, France

[7] Diderot Univ, Sorbonne Paris Cite, Paris, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159544

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：8022 / 8023

页数：2

共 50 条

[21] Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Daniele, Patrick
Tomaras, Dimitrios
Tremblay, Gabriel
Casasnovas, Rene-Olivier
Maerevoet, Marie
Zijlstra, Josee
Follows, George
Vermaat, Joost S. P.
Kalakonda, Nagesh
Goy, Andre Henri
Choquet, Sylvain
Van den Neste, Eric
Hill, Brian T.
Thieblemont, Catherine
Cavallo, Federica
de la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Bouabdallah, Reda
Jager, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vasilakopoulos, Theodoros P.
Samal, Priyanka
Nagy, Agnes
Ku, Matthew
Canales Albendea, Miguel Angel
FUTURE ONCOLOGY, 2021, 17 (11) : 1295 - 1310
[22] Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma
Salles, Gilles
Wang, Anthony
Mutebi, Alex
Alshreef, Abualbishr
Davies, Kalatu R.
van de Wetering, Gijs
Chirikov, Viktor
BLOOD, 2022, 140 : 10934 - 10935
[23] Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma
Li, Tommy
Gibiansky, Leonid
Parikh, Apurvasena
Putnins, Matthew
Chiu, Christopher W.
Sacchi, Mariana
Feng, Huaibao
Ahmadi, Tahamtan
Gupta, Manish
Xu, Steven
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
[24] Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
Iskierka-Jazdzewska, Elzbieta
Kim, Won Seog
Cho, Seok-Goo
Kim, Tae Min
Jarque, Isidro
Robak, Tadeusz
Poon, Michelle
Prince, H. Miles
Yong, Sung
Lim, Francesca
Carpio, Cecilia
Tan, Tran-Der
Ayyappan, Sabarish
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ivanescu, Cristina
BLOOD, 2023, 142
[25] Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin's lymphoma (RR-NHL).
Lin, Vincent
Oak, Bhagyashree
Snider, Julia
Epstein, Josh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1-3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)
Sharman, Jeff P.
Boccia, Ralph, V
Doerr, Thomas
Conte, Kristin
Bai, Yang
Elliott, Brian
Andorsky, David J.
BLOOD, 2022, 140 : 9491 - 9492
[27] Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6
Andorsky, David Jacob
Boccia, Ralph V.
Lash, Bradley Walter
Vaidya, Rakhee
Gandhi, Mitul
Patel, Ameet
Ibrahimi, Sami
Madueno, Fernando Manuel Vargas
Lee, Christina Y.
Naik, Seema
Haydu, J. Erika
Fesler, Mark
Osei-Bonsu, Kojo
Conte, Kristin
Doerr, Thomas
Bai, Yang
Sacchi, Mariana
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
Linton, Kim
Jurczak, Wojciech
Lugtenburg, Pieternella
Gyan, Emmanuel
Balari, Anna Maria Sureda
Christensen, Jacob Haaber
Hess, Brian
Tilly, Herve
Cordoba, Raul
Lewis, David
Okada, Craig
Hutchings, Martin
Clausen, Michael Roost
Vitolo, Umberto
Cochrane, Tara
Leppa, Sirpa
Chamuleau, Martine E. D.
Conlon, Rebekah
Favaro, Elena
Gernhardt, Diana
Altintas, Isil
Liu, Yan
Thieblemont, Catherine
BLOOD, 2023, 142
[29] EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL
Vose, Julie
Vitolo, Umberto
Lugtenburg, Pieternella
Chamuleau, Martine E. D.
Linton, Kim M.
Thieblemont, Catherine
Sonnevi, Kristina
Jurczak, Wojciech
Olszewski, Adam J.
Awan, Farrukh Tauseef
Okada, Craig Y.
Feldman, Tatyana A.
Hutchings, Martin
Favaro, Elena
Hoehn, Daniela
Li, Zhu
Conlon, Rebekah
Sancho, Juan-Manuel
Chavez, Julio C.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[30] Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
Blum, Jordan
Masters, Gregg
Chiu, Christopher
Si, Han
Gale, Jeremy
Grimm, Lisa
Ma-Edmonds, Manling
Loya, Matthew
Bachu, Mahesh
Jabado, Omar
Soong, David
Zhang, Jimin
Wielgos-Bonvallet, Monica
Bottrel, Nicole
Henitz, Erin
Higgs, Brandon
Sasser, Kate
Jure-Kunkel, Maria
Fereshteh, Mark
BLOOD, 2022, 140 : 6453 - 6454

← 1 2 3 4 5 →